Drug intelligence / Profile preview

LPM5260558

Development stage: Unknown
Lead developer: Shandong Quanzhong Biomedical Technology
Modality: Small Molecules
Administration: Intravenous

Overview

LPM5260558 is a small molecule P2X7 receptor antagonist under development by Shandong Quanzhong Biopharmaceutical (a subsidiary of Luye Pharma Group) for the treatment of acute ischemic stroke (AIS). The P2X7 receptor is an ATP-gated ion channel primarily expressed on microglia in the central nervous system; its activation triggers the release of pro-inflammatory cytokines like IL-1β and IL-18, contributing to neuroinflammation and secondary brain injury after an ischemic event. By inhibiting P2X7, LPM5260558 aims to provide neuroprotection and improve functional recovery. It is currently being evaluated in Phase 1 clinical trials for safety, tolerability, and pharmacokinetics in healthy volunteers.

Targets

P2RX7 (P2X purinoceptor 7)

Beyond the preview

Go deeper on LPM5260558.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LPM5260558.

Explore the full profile